Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $1.13B. Across the group, the median move over the past trading day is +1.80%. Price change over the past year runs from −37.8% to +3.4% across the middle 80 percent of the group, with a median of −13.3%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | +1.03% | Aug 27, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% | Aug 27, 2026 |
| PSH0.DE | Sernova Biotherapeutics Inc | $30.82M | Micro cap | −27.68% | Sep 10, 2026 |
| SVA.TO | Sernova Biotherapeutics Inc | $29.93M | Micro cap | −42.11% | Sep 10, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.